UltraGreen.ai gains Singapore approval for Verdye in regional push

The regulatory clearance anchors UltraGreen.ai's Southeast Asia expansion.

UltraGreen.ai has secured regulatory approval in Singapore for Verdye, or indocyanine green for injection, which will support its expasion in Southeast Asia.

In a press release, the company said the approval gives the company access to Singapore’s healthcare system, noting Singapore acts as a centre for clinical practice and regional influence in healthcare adoption. 

The approval also supports its commercialisation efforts and partnerships with hospitals and healthcare institutions in the city-state.

Verdye is used in fluorescence-guided surgery with indocyanine green, applied in oncology, colorectal, reconstructive, and vascular procedures.

UltraGreen.ai develops a fluorescence-guided surgery platform combining pharmaceutical products, imaging hardware, and artificial intelligence-based data tools for surgical decision-making and procedural standardisation.

The company said the platform supports wider adoption of fluorescence-guided surgery across procedures.

Ravi Sajwan, CEO of UltraGreen.ai, said Singapore serves as a strategic market due to its healthcare system and regional role in clinical adoption across Southeast Asia, adding that the approval supports regulatory execution and the company’s regional strategy.

Verdye is approved in 41 countries, whilst the IC-Flow imaging system is approved in 45 markets.

UltraGreen.ai also referenced its recent initial public offering and regulatory approval of Verdye in the Philippines as part of its Southeast Asia expansion.